COLA: Drug Challenges and Desensitization

Price: FREE for members, $35 non-members

Session recorded on August 3, 2018

Speaker: Rebecca Saff, MD, PhD

Viewers can earn credit by completing the posttest questions.

The importance of appropriate drug allergy evaluation is becoming clearer as the use of alternative medications, when not necessary, can have consequences in the treatment of certain diseases.  Allergists need to understand how to appropriately evaluate a drug hypersensitivity reaction including skin testing and test dose as appropriate and when to recommend desensitization and how the procedure should be performed.  This allows patients to receive the optimal treatment that is required for their disease. This video covers evaluation, options for management, indications, and risks of drug challenges and desensitization.

Target Audience

Practicing Allergists / Immunologists
Fellows-in-Training

Learning Objectives

After viewing the video recording, learners should be able to…

  • Discuss how to the evaluate and manage patients with drug hypersensitivity reactions
  • Consider when performing an oral drug challenge (test dose) is appropriate
  • Review indications, risks and benefits of drug desensitization

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support
There is no commercial support for this activity.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity.

Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.

Jay Portnoy, MD, Planner
Speaker, Honorarium: Thermofisher, Boehringer Ingelheim

The following have no financial relationships to disclose:

Paul Dowling, MD, Planner
Rebecca Saff, MD, PhD, Speaker

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
08/18/2017
Course expires: 
12/31/2018
Cost:
$35.00
Rating: 
0

Rebecca Saff, MD, PhD
Division of Rheumatology, Allergy & Immunology
Massachusetts General Hospital
Boston, MA

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support
There is no commercial support for this activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance

Price

Cost:
$35.00
Please login or create an account to take this course.